Inhibitor of indoleamine 2,3-dioxygenase-1 and methods of manufacture and use thereof
AssigneeUniversity Health Network
InventorsDonald WEAVER, Michael G. BRANT, Stephanie WOHNIG, Fan WU, Jake GOODWIN-TINDALL, Autumn MEEK, Paolo SCHIAVINI
Life of this patent
Estimating the term…
Abstract
Inhibition of indoleamine 2,3-dioxygenase (IDO1) is an attractive immunotherapeutic approach for the treatment of a variety of cancers. Dysregulation of this enzyme has also been implicated in other severe diseases such as Alzheimer's disease and arthritis. Small molecule inhibitors of IDO, syntheses, and uses thereof are provided.
Claims13
1-7. (canceled)
A method of treating a disease associated with tryptophan metabolism in a subject, the method comprising administering a therapeutically effective amount to a subject of a compound, or a pharmaceutically acceptable salt thereof, of either of Formulas I:
- wherein
- X is H, F, Cl, or Br;
- R1 is piperidin-2-yl, 1-phenylmethan-1 -yl-1-ol, pyrrol-2-yl, or
- and R2, R3, R4, R5, and R6 are each independently H, F, Cl, amino, hydroxy, alkoxy, cyano, trifluoromethyl, or phenyl.
13-19. (canceled)
Dependencies are inferred from the claim text.